Omalizumab in allergic diseases, a recent review
Omalizumab in allergic diseases, a recent review
About this item
Full title
Author / Creator
Publisher
Thailand: The Allergy and Immunology Society
Journal title
Language
English
Formats
Publication information
Publisher
Thailand: The Allergy and Immunology Society
Subjects
More information
Scope and Contents
Contents
Omalizumab is a biological engineered molecule, targeting the Cepsilon3 domain of the IgE molecule. It binds with free IgE and prevents free IgE from attaching to high-affinity IgE receptor (FcepsilonRI) on effector cells such as mast cells, basophils and also on dendritic cells. The result is a blocking of mediator release from these cells and the...
Alternative Titles
Full title
Omalizumab in allergic diseases, a recent review
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_902677394
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_902677394
Other Identifiers
ISSN
0125-877X
